Trial reportNeurourology and urodynamics2021
OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children.
Trial report in Neurourology and urodynamics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Pooled it
- Long-term Safety and Tolerability of Repeated Treatments With OnabotulinumtoxinA in Children With Neurogenic Detrusor Overactivity.The Journal of urology · 2023Trial
- OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children.Neurourology and urodynamics · 2021Trial
- Botulinum Toxin in Children and Adolescents-A Comprehensive Review of Clinical Applications.Toxins · 2026Review
- Protocol-driven botulinum toxin injections for pediatric neurogenic bladder: long-term continence and bladder outcomes supporting its role as a minimally invasive alternative to augmentation cystoplasty.World journal of urology · 2026Article
- Phenotyping Overactive Bladder - Part 2: Can Management be Improved by Phenotyping, and Targeting Therapy According to Urgency Type and Other Characteristics? ICI-RS 2025.Neurourology and urodynamics · 2026Review
- Advancements in the Treatment and Management of Voiding Dysfunction in Individuals with Spina Bifida.Current urology reports · 2026Review
- Safety of 200iU of intravesical Botox in children of all ages with functional urinary incontinence.Pediatric surgery international · 2025Article
- A Novel Approach to Botulinum Toxin Injection for Neurogenic Detrusor Overactivity in Children.Cureus · 2025Article
- Review
- Review
- Article
- Autonomic dysreflexia in urological practice: pathophysiology, prevention and treatment considerations.World journal of urology · 2024Review
- OnabotulinumtoxinA is now an important tool for managing pediatric neurogenic lower urinary tract dysfunction.Frontiers in pediatrics · 2024Review
- Quality of Life in Female Patients with Overactive Bladder after Botulinum Toxin Treatment.Toxins · 2023Article
- 2023 Canadian Urological Association/Pediatric Urologists of Canada guideline: Pediatric patients with neurogenic lower urinary tract dysfunction Full-text version.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Onabotulinum Toxin A Intradetrusor Injections in Children with Neurogenic Lower Urinary Tract Dysfunction: Long-Term Histological Effects on the Bladder Wall.Biomedicines · 2023Article
- Review
- Review
- Onabotulinumtoxin A (Botox): A reasonable alternative for refractory neurogenic bladder dysfunction in children and young adults.Neurourology and urodynamics · 2021Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
Abstract
aimsThis study evaluated whether one (or more) of three doses of onabotulinumtoxinA were safe and effective to treat neurogenic detrusor overactivity (NDO) in children.
methodsThis was a 48-week prospective, multicenter, randomized, double-blind study in children (aged 5-17 years) with NDO and urinary incontinence (UI) receiving one onabotulinumtoxinA treatment (50, 100, or 200 U; not to exceed 6 U/kg). Primary endpoint: change from baseline in daytime UI episodes. Secondary endpoints: change from baseline in urine volume at first morning catheterization, urodynamic measures, and positive response on the treatment benefit scale. Safety was also assessed.
resultsThere was a similar reduction in urinary incontinence from baseline to Week 6 for all doses (-1.3 episodes/day). Most patients reported positive responses on the treatment benefit scale (75.0%-80.5%). From baseline to Week 6, increases were observed in urine volume at first morning clean intermittent catheterization (50 U, 21.9 ml; 100 U, 34.9 ml; 200 U, 87.5 ml; p = 0.0055, 200 U vs. 50 U) and in maximum cystometric capacity (range 48.6-63.6 ml) and decreases in maximum detrusor pressure during the storage phase (50 U, -12.9; 100 U, -20.1; 200 U, -27.3 cmH
conclusionsOnabotulinumtoxinA was well tolerated and effective for the treatment of NDO in children; 200 U showed greater efficacy in reducing bladder pressure and increasing bladder capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.